文献速递冠心病

PCI术后长期维持单抗:氯吡格雷对比阿司匹林HOST-EXAM扩展研究

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
PubMed 文献 · Circulation · 2022-11-07

HOST-EXAM扩展研究对药物洗脱支架PCI术后维持双抗12±6个月无临床事件的患者进行延长随访。中位随访5.8年,氯吡格雷单药治疗较阿司匹林单药显著降低主要复合终点、血栓终点及出血终点,全因死亡无差异。

要点

  • DES-PCI术后双抗12±6月无事件者,氯吡格雷单药长期疗效优于阿司匹林。
  • 氯吡格雷降低主要复合终点(HR 0.74)、血栓终点(HR 0.66)及出血终点(HR 0.74)。
  • 两组全因死亡无显著差异(HR 1.04,P=0.742)。

核心结论

  • 在PCI后维持双抗12±6个月无临床事件的患者中,延长随访>5年,氯吡格雷单药较阿司匹林单药降低复合净临床终点发生率。

研究设计与样本

  • HOST-EXAM试验的试验后延长随访研究,2014年3月至2018年5月随机分配5438例DES-PCI后维持双抗12±6个月无临床事件的患者1:1接受氯吡格雷75mg每日一次或阿司匹林100mg每日一次。
  • 延长随访分析基于符合方案人群(氯吡格雷组2431例,阿司匹林组2286例)。

主要发现

  • 中位随访5.8年(IQR 4.8-6.2年),主要终点在氯吡格雷组和阿司匹林组分别发生12.8%和16.9%(HR 0.74,95%CI 0.63-0.86,P<0.001)。
  • 次要血栓终点发生率氯吡格雷组7.9% vs 阿司匹林组11.9%(HR 0.66,95%CI 0.55-0.79,P<0.001)。
  • 次要出血终点发生率氯吡格雷组4.5% vs 阿司匹林组6.1%(HR 0.74,95%CI 0.57-0.94,P=0.016)。
  • 全因死亡发生率两组无显著差异(6.2% vs 6.0%;HR 1.04,95%CI 0.82-1.31,P=0.742)。
  • 2年界标分析显示氯吡格雷的获益在整个随访期间一致。

关键数值与推荐

  • 主要终点为全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3型或以上出血的复合终点。
  • 次要血栓终点为心源性死亡、非致死性心肌梗死、缺血性卒中、因ACS再入院及确定或可能的支架血栓。
  • 出血终点为BARC 2型或以上出血。

临床怎么用

  • 对于DES-PCI术后维持双抗12±6个月无临床事件的患者,长期维持单抗治疗时可考虑氯吡格雷而非阿司匹林。
  • 选择氯吡格雷单药需权衡缺血与出血风险,本研究中氯吡格雷同时降低血栓和出血终点。

局限性

  • 分析基于符合方案人群,非意向性治疗人群。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial. METHODS: From March 2014 through May 2018, 5438 patients who maintained dual antiplatelet therapy without clinical events for 12±6 months after percutaneous coronary intervention with drug-eluting stents were randomly assigned in a 1:1 ratio to receive clopidogrel (75 mg once daily) or aspirin (100 mg once daily). The primary end point (a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission attributable to acute coronary syndrome, and Bleeding Academic Research Consortium type 3 or greater bleeding), secondary thrombotic end point (cardiac death, nonfatal myocardial infarction, ischemic stroke, readmission attributable to acute coronary syndrome, and definite or probable stent thrombosis), and bleeding end point (Bleeding Academic Research Consortium type 2 or greater bleeding) were analyzed during the extended follow-up period. Analysis was performed on the per-protocol population (2431 patients in the clopidogrel group and 2286 patients in the aspirin group). RESULTS: During a median follow-up of 5.8 years (interquartile range, 4.8-6.2 years), the primary end point occurred in 12.8% and 16.9% in the clopidogrel and aspirin groups, respectively (hazard ratio, 0.74 [95% CI, 0.63-0.86]; P<0.001). The clopidogrel group had a lower risk for the secondary thrombotic end point (7.9% versus 11.9%; hazard ratio, 0.66 [95% CI, 0.55-0.79]; P<0.001) and secondary bleeding end point (4.5% versus 6.1%; hazard ratio, 0.74 [95% CI, 0.57-0.94]; P=0.016). There was no significant difference in the incidence of all-cause death between the 2 groups (6.2% versus 6.0%; hazard ratio, 1.04 [95% CI, 0.82-1.31]; P=0.742). Landmark analysis at 2 years showed that the beneficial effect of clopidogrel was consistent throughout the follow-up period. CONCLUSIONS: During an extended follow-up of >5 years after randomization, clopidogrel monotherapy compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after percutaneous coronary intervention with drug-eluting stents. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02044250.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kang, Park, Lee, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation. 2022. PMID: 36342475. doi:10.1161/CIRCULATIONAHA.122.062770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。